scholarly journals Multiple Antigenic Peptide-Based Vaccines Targeting Ixodes ricinus Neuropeptides Induce a Specific Antibody Response but Do Not Impact Tick Infestation

Pathogens ◽  
2020 ◽  
Vol 9 (11) ◽  
pp. 900
Author(s):  
Consuelo Almazán ◽  
Ladislav Šimo ◽  
Lisa Fourniol ◽  
Sabine Rakotobe ◽  
Jérémie Borneres ◽  
...  
Keyword(s):  
Antibody Response ◽  
Ixodes Ricinus ◽  
Antigenic Peptide ◽  
Tick Feeding ◽  
Igg Antibody ◽  
Individual Level ◽  
Multiple Antigenic Peptide ◽  
New Strategy ◽  
The Individual ◽  
Antibody Levels

Synthetic peptide vaccines were designed to target the neuropeptides innervating Ixodes ricinus salivary glands and hindgut and they were tested for their capacity to afford protective immunity against nymphs or larvae and Anaplasma phagocytophilum-infected nymph infestation, in mice and sheep, respectively. In both models, the assembly of SIFamide (SIFa) or myoinhibitory peptide (MIP) neuropeptides into multiple antigenic peptide constructs (MAPs) elicited a robust IgG antibody response following immunization. Nevertheless, no observable detrimental impact on nymphs was evidenced in mice, and, unfortunately, the number of engorged nymphs on sheep was insufficient for firm conclusions to be drawn, including for bacterial transmission. Regarding larvae, while vaccination of the sheep did not globally diminish tick feeding success or development, analyses of animals at the individual level revealed a negative correlation between anti-SIFa and MIP antibody levels and larva-to-nymph molting success for both antigens. Our results provide a proof of principle and precedent for the use of MAPs for the induction of immunity against tick peptide molecules. Although the present study did not provide the expected level of protection, it inaugurates a new strategy for protection against ticks based on the immunological targeting of key components of their nervous system.

Persisting Antibody Response 9 Years After Bivalent Human Papillomavirus (HPV) Vaccination in a Cohort of Dutch Women: Immune Response and the Relation to Genital HPV Infections

2020 ◽  
Vol 221 (11) ◽  
pp. 1884-1894 ◽  
Author(s):  
Joske Hoes ◽  
Hella Pasmans ◽  
Mirjam J Knol ◽  
Robine Donken ◽  
Naomi van Marm-Wattimena ◽  
...  
Keyword(s):  
Human Papillomavirus ◽  
Antibody Response ◽  
Hpv Vaccination ◽  
Hpv Infection ◽  
Consistent Difference ◽  
Individual Level ◽  
Persistent Infections ◽  
The Individual ◽  
High Risk Hpv ◽  
Antibody Levels

Abstract The bivalent human papillomavirus (HPV) vaccine is highly effective and induces robust serological responses. Using a Dutch prospective cohort initiated in 2009, including 744 vaccinated and 294 unvaccinated girls (1993–1994) who provide a vaginal self-swab sample, serum sample, and questionnaire yearly, we report a high, persisting antibody response up to 9 years after vaccination for vaccine types HPV-16 or HPV-18. Antibodies against nonvaccine HPV types 31, 33, 45, 52, and 58 were lower but still significantly higher than in unvaccinated individuals. This was also reflected in the seroprevalence. We compared participant characteristics and antibody levels between vaccinated women with and those without HPV infections 1 year before infection (204 incident and 64 persistent infections), but we observed no consistent difference in type-specific antibody levels. Having a high-risk HPV infection was associated with sexual risk behavior and smoking 1 year before infection. Although high antibody levels are necessary for protection, our study suggests that on the individual level other factors such as HPV exposure or antibody avidity could be important.

Immunologic Response to Pneumococcal Polysaccharide Vaccine in Infants

1980 ◽  
Vol 89 (3_suppl) ◽  
pp. 351-356 ◽  
Author(s):  
John L. Sloyer ◽  
Laurel J. Karr ◽  
John H. Ploussard ◽  
Gerald D. Schiffman
Keyword(s):  
Antibody Response ◽  
Otitis Media ◽  
Natural Infection ◽  
Young Infant ◽  
Serum Antibody ◽  
Capsular Polysaccharides ◽  
Igg Antibody ◽  
Nasopharyngeal Colonization ◽  
Antibody Levels ◽  
Group 1

The serum antibody response to purified pneumococcal capsular polysaccharides (PCP) was determined in four groups of infants ranging in age from 3 to 24 months. Group 1 consisted of eight infants immunized with an octavalent vaccine containing serotypes 1, 3, 6, 7, 14, 18, 19 and 23 (PCP-8). Group 1 received 25 μg of each serotype at 3–6 months of age and again at 18–24 months. The antibody response after the second immunization was compared to a group of nine patients receiving a primary immunization at 18–24 months and to a group of ten age-matched controls receiving saline placebo. There were no significant differences in mean serum antibody levels between the two groups receiving the PCP-8. A fourth group of 44 infants between 6 and 21 months of age received either PCP-7 or PCP-8 and were followed for two years, at which time simultaneous injections of both vaccines were administered. Types 2, 3, 7, and 8 were most immunogenic but levels six months after immunization were approximately the same as for unimmunized controls with the exception of serotypes 3 and 7 which persisted for about two years. The class of antibody induced either by natural infection or by immunization was preferentially IgG and it was more often induced by the former. There were no significant differences between the serotypes of pneumococci isolated from nasopharyngeal cultures regardless of which vaccine was administered. Finally, the least immunogenic serotypes include 4, 6, 14, 19, and 23 and these are the only serotypes thus far associated with otitis media after immunization. The results suggest that PCP do not induce a lasting immune tolerance at the dose administered in this study; PCP are not very immunogenic in the young infant; PCP antibody tends to rise naturally; IgG antibody is preferentially induced; nasopharyngeal colonization is not altered by PCP immunization; and an association may exist between PCP immunogenicity and subsequent onset of otitis media.

scholarly journals The Correlation Between IgM and IgG Antibodies With Blood Profile In Patients Infected With COVID 19

2021 ◽  
Author(s):  
Zahra Alibolandi ◽  
Amirreza Ostadian ◽  
Saeed Sayyah ◽  
Hamed Haddad Kashani ◽  
Hassan Ehteram ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Antibody Response ◽  
Laboratory Data ◽  
Severe Illness ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Blood Profile ◽  
Virus Exposure ◽  
Antibody Levels

Abstract Objectives: This study aimed to determine the levels of IgM and IgG antibody response to the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with different disease severity.Methods: IgM and IgG antibody levels were evaluated via enzyme-linked immunosorbent assay (ELISA). In total, 100 patients with confirmed SARS-CoV-2 infection were enrolled in this study and viral RNA was detected by using Real-time PCR technique. Clinical and laboratory data were collected and analyzed after hospital admission for COVID-19 and two months post-admission. Results: The level of anti-SARS-CoV-2 antibody IgG was significantly higher in the severe patients than those in moderate and mild groups, 2 months after admission. Also, level of IgG was positively associated with increased WBC, NUT and LYM counts in sever than mild or moderate groups after admission to hospital.Conclusion: Our findings suggested that patients with severe illness might experience longer virus exposure times and have a stronger antibody response against viral infection. Thus, they have longer time immunity compared with other groups.

scholarly journals Detailed Multiplex Analysis of SARS-CoV-2 Specific Antibodies in COVID-19 Disease

2021 ◽  
Vol 12 ◽  
Author(s):  
Siggeir F. Brynjolfsson ◽  
Hildur Sigurgrimsdottir ◽  
Elin D. Einarsdottir ◽  
Gudrun A. Bjornsdottir ◽  
Brynja Armannsdottir ◽  
...  
Keyword(s):  
Antibody Response ◽  
Immunological Response ◽  
Receptor Binding Domain ◽  
Igg Antibody ◽  
Nucleocapsid Proteins ◽  
The Third ◽  
Antibody Isotypes ◽  
Iga Antibodies ◽  
Set Up ◽  
Antibody Levels

A detailed understanding of the antibody response against SARS-CoV-2 is of high importance, especially with the emergence of novel vaccines. A multiplex-based assay, analyzing IgG, IgM, and IgA antibodies against the receptor binding domain (RBD), spike 1 (S1), and nucleocapsid proteins of the SARS-CoV-2 virus was set up. The multiplex-based analysis was calibrated against the Elecsys® Anti-SARS-CoV-2 assay on a Roche Cobas® instrument, using positive and negative samples. The calibration of the multiplex based assay yielded a sensitivity of 100% and a specificity of 97.7%. SARS-CoV-2 specific antibody levels were analyzed by multiplex in 251 samples from 221 patients. A significant increase in all antibody types (IgM, IgG, and IgA) against RBD was observed between the first and the third weeks of disease. Additionally, the S1 IgG antibody response increased significantly between weeks 1, 2, and 3 of disease. Class switching appeared to occur earlier for IgA than for IgG. Patients requiring hospital admission and intensive care had higher levels of SARS-CoV-2 specific IgA levels than outpatients. These findings describe the initial antibody response during the first weeks of disease and demonstrate the importance of analyzing different antibody isotypes against multiple antigens and include IgA when examining the immunological response to COVID-19.

scholarly journals Comparative evaluation of SARS-CoV-2 IgG assays against nucleocapsid and spike antigens

2021 ◽  
pp. 1-5
Author(s):  
Mitra Rezaei ◽  
Mohammadhadi Sadeghi ◽  
Alireza Korourian ◽  
Payam Tabarsi ◽  
Mihan Porabdollah ◽  
...  
Keyword(s):  
Antibody Response ◽  
Symptom Onset ◽  
Disease Onset ◽  
Early Time ◽  
Igg Antibody ◽  
Cell Percentage ◽  
Percent Positivity ◽  
Severity Of The Disease ◽  
Nucleoprotein N ◽  
Antibody Levels

BACKGROUND: There are few studies to compare antibody response against anti-spike (S) and anti- nucleoprotein (N) SARS-CoV-2. OBJECTIVE: The aim of this study was to evaluate the IgG antibody production against S and N antigens of the virus and their correlation with the time and severity of the disease. METHODS: The IgG antibodies against S and N antigens of SARS-CoV-2 in serum specimens 72 symptomatic patients who tested real-time reverse transcription polymerase chain reaction positive for SARS-CoV-2 were detected using the ELISA technique. Different antibody response was compared and the correlation with the time from disease onset and the severity was evaluated. RESULTS: Forty-eight of 72 (67%) patients tested positive for anti-SARS-CoV-2 antibodies, while 24 (33%) did not have detectable antibodies. Comparison of antibody levels for N and S antibodies showed that they correlate with each other well (r= 0.81; P< 0.001). However, sensitivity of anti-S SARS-CoV-2 IgG and anti-N SARS-CoV-2 IgG was 30% and 60%, during the first 7 days after symptom onset (r= 0.53; P= 0.111), but increased to 73% and 68% at more than 1-week post symptom onset (r= 0.89, P= 0.111), respectively. Cases with positive IgG response showed a decreased CD8 cell percentage compared to the negative IgG groups (26 ± 14 vs. 58 ± 32, p= 0.066 in anti-N IgG group and 28 ± 15 vs. 60 ± 45, p= 0.004 in anti-S IgG group, respectively). CONCLUSION: Nearly one-third of the confirmed COVID-19 patients had negative serology results. Lower percent positivity at early time points after symptom onset (less than 1 week) was seen using anti-S SARS-COV-2 IgG kit compare to the anti-N SARS-CoV-2 IgG; therefore, clinicians should interpret negative serology results of especially anti-S SARS-CoV-2 IgG with caution.

scholarly journals Pre-vaccination and early B cell signatures predict antibody response to SARS-CoV-2 mRNA vaccine

2021 ◽  
Author(s):  
Lela Kardava ◽  
Nicholas Rachmaninoff ◽  
William Lau ◽  
Clarisa Buckner ◽  
Krittin Trihemasava ◽  
...  
Keyword(s):  
Antibody Response ◽  
B Cell ◽  
Response Variability ◽  
Antibody Responses ◽  
Igg Antibody ◽  
Memory B Cell ◽  
Post Vaccination ◽  
Highly Effective ◽  
Antibody Levels ◽  
Early Indicators

SARS-CoV-2 mRNA vaccines are highly effective, although weak antibody responses are seen in some individuals with correlates of immunity that remain poorly understood. Here we longitudinally dissected antibody, plasmablast, and memory B cell (MBC) responses to the two-dose Moderna mRNA vaccine in SARS-CoV-2-uninfected adults. Robust, coordinated IgA and IgG antibody responses were preceded by bursts of spike-specific plasmablasts after both doses, but earlier and more intensely after dose two. Distinct antigen-specific MBC populations also emerged post-vaccination with varying kinetics. We identified antigen non-specific pre-vaccination MBC and post-vaccination plasmablasts after dose one and their spike-specific counterparts early after dose two that correlated with subsequent antibody levels. These baseline and response signatures can thus provide early indicators of serological efficacy and explain response variability in the population.

scholarly journals Occurrence of BNT162b2 Vaccine Adverse Reactions Is Associated with Enhanced SARS-CoV-2 IgG Antibody Response

Vaccines ◽  
2021 ◽  
Vol 9 (9) ◽  
pp. 977
Author(s):  
Yoav Rechavi ◽  
Moshe Shashar ◽  
Jonathan Lellouche ◽  
Moshe Yana ◽  
Daniel Yakubovich ◽  
...  
Keyword(s):  
Adverse Reaction ◽  
Immune System ◽  
Antibody Response ◽  
Adverse Reactions ◽  
Vaccine Hesitancy ◽  
Clear Correlation ◽  
Igg Antibody ◽  
Global Mission ◽  
Antibody Levels ◽  
Vaccination Hesitancy

Promoting SARS-CoV-2 vaccination has been a global mission since the first vaccines were approved for emergency use. Alongside the excitement following the possibility of eradicating SARS-CoV-2 and ending the COVID-19 pandemic, there has been ample vaccine hesitancy, some due to the abundant reporting of adverse reactions. We report here that the occurrence of BNT162b2 vaccine adverse reactions is associated with enhanced antibody response. We found a statistically significant correlation between having an adverse reaction, whether local or systemic, and higher antibody levels. No sex difference was observed in antibody levels. However, as was recently reported, the antibody response was found to be lower among older vaccinees. The demonstration of a clear correlation between adverse reactions and antibody levels may help reduce vaccination hesitancy by reassuring that the presence of such reactions is an indication of a well-functioning immune system.

scholarly journals Serology assessment of antibody response to SARS-CoV-2 in patients with COVID-19 by rapid IgM/IgG antibody test

2020 ◽  
Author(s):  
Yang De Marinis ◽  
Torgny Sunnerhagen ◽  
Pradeep Bompada ◽  
Anna Blackberg ◽  
Runtao Yang ◽  
...  
Keyword(s):  
Antibody Response ◽  
Disease Duration ◽  
Disease Onset ◽  
Antibody Test ◽  
Population Level ◽  
Distribution Patterns ◽  
Hospitalized Patients ◽  
Antibody Detection ◽  
Igg Antibody ◽  
The Individual

The coronavirus disease 2019 (COVID-19) pandemic has created a global health- and economic crisis. Lifting confinement restriction and resuming to normality depends greatly on COVID-19 immunity screening. Detection of antibodies to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) which causes COVID-19 by serological methods is important to diagnose a current or resolved infection. In this study, we applied a rapid COVID-19 IgM/IgG antibody test and performed serology assessment of antibody response to SARS-CoV-2. In PCR-confirmed COVID-19 patients (n=45), the total antibody detection rate is 92% in hospitalized patients and 79% in non-hospitalized patients. We also studied antibody response in relation to time after symptom onset and disease severity, and observed an increase in antibody reactivity and distinct distribution patterns of IgM and IgG following disease progression. The total IgM and IgG detection is 63% in patients with < 2 weeks from disease onset; 85% in non-hospitalized patients with > 2 weeks disease duration; and 91% in hospitalized patients with > 2 weeks disease duration. We also compared different blood sample types and suggest a potentially higher sensitivity by serum/plasma comparing with whole blood measurement. To study the specificity of the test, we used 69 sera/plasma samples collected between 2016-2018 prior to the COVID-19 pandemic, and obtained a test specificity of 97%. In summary, our study provides a comprehensive validation of the rapid COVID-19 IgM/IgG serology test, and mapped antibody detection patterns in association with disease progress and hospitalization. Our study supports that the rapid COVID-19 IgM/IgG test may be applied to assess the COVID-19 status both at the individual and at a population level.

scholarly journals The Correlation between IgM and IgG Antibodies with Blood Profile in Patients Infected with COVID 19

2021 ◽  
Author(s):  
Zahra Alibolandi ◽  
Amirreza Ostadian ◽  
Saeed Sayyah ◽  
Hamed Haddad Kashani ◽  
Hassan Ehteram ◽  
...  
Keyword(s):  
Severe Acute Respiratory Syndrome ◽  
Antibody Response ◽  
Laboratory Data ◽  
Severe Illness ◽  
Enzyme Linked Immunosorbent Assay ◽  
Igg Antibodies ◽  
Igg Antibody ◽  
Blood Profile ◽  
Virus Exposure ◽  
Antibody Levels

Abstract Objectives: This study aimed to determine the levels of IgM and IgG antibody response to the severe acute respiratory syndrome coronavirus (SARS-CoV)-2 in coronavirus disease 2019 (COVID-19) patients with different disease severity.Methods: IgM and IgG antibody levels were evaluated via enzyme-linked immunosorbent assay (ELISA). In total, 100 patients with confirmed SARS-CoV-2 infection were enrolled in this study and viral RNA was detected by using Real-time PCR technique. Clinical and laboratory data were collected and analyzed after hospital admission for COVID-19 and two months post-admission. Results: The level of anti-SARS-CoV-2 antibody IgG was significantly higher in the severe patients than those in moderate and mild groups, 2 months after admission. Also, level of IgG was positively associated with increased WBC, NUT and LYM counts in sever than mild or moderate groups after admission to hospital.Conclusion: Our findings suggested that patients with severe illness might experience longer virus exposure times and have a stronger antibody response against viral infection. Thus, they have longer time immunity compared with other groups.

Polymorphism in the IL-1β promoter is associated with IgG antibody response to circumsporozoite protein repeats of Plasmodium vivax

2020 ◽  
Vol 114 (11) ◽  
pp. 858-865
Author(s):  
Marcela Petrolini Capobianco ◽  
Gustavo Capatti Cassiano ◽  
Luciane Moreno Storti-Melo ◽  
Tamirys Simão Pimenta ◽  
Ana Paula Drummond Rodrigues ◽  
...  
Keyword(s):  
Antibody Response ◽  
Plasmodium Vivax ◽  
Circumsporozoite Protein ◽  
Igg Antibody ◽  
Specific Pcr ◽  
Pcr Rflp ◽  
Allele Specific ◽  
Study Association ◽  
Antibody Levels ◽  
Host Parasite

Abstract Background It is well established that infection by Plasmodium vivax is a result of host-parasite interactions. In the present study, association with the IL1/IL2 cytokine profiles, anticircumsporozoite protein antibody levels and parasitic loads was evaluated in individuals naturally infected with P. vivax in an endemic area of the Brazilian Amazon. Methods Molecular diagnosis of P. vivax and variants was performed using the PCR-RFLP method and IL1B -511C&gt;T, IL2 -330T&gt;G and IL2+114T&gt;G polymorphisms were identified using PCR-RFLP and allele-specific PCR. IL-1β and IL-2 cytokine levels were detected by flow cytometry and circumsporozoite protein (CSP) antibodies were measured by ELISA. Results Three variants of P. vivax CSP were identified and VK247 was found to be the most frequent. However, the prevalence and magnitude of IgG antibodies were higher for the VK210 variant. Furthermore, the antibody response to the CSP variants was not associated with the presence of the variant in the infection. Significant differences were observed between the single nucleotide polymorphism (SNP) -511T&gt;C in the IL1B gene and levels of antibodies to the VK247 and P. vivax-like variants, but there were no associations between SNPs in IL1 and IL2 genes and their plasma products. Conclusions Individuals with the rs16944 CC genotype in the IL1β gene have higher antibody levels to the CSP of P. vivax of VK247 and P. vivax-like variants.

Sign in / Sign up

Export Citation Format

Share Document